Sareum Holdings plc Announces Details for Upcoming AGM
Sareum Holdings plc Announces Details for Upcoming AGM
Sareum Holdings plc (AIM: SAR) is a biotechnology company based in the UK, focused on innovating kinase inhibitors aimed at treating autoimmune diseases and cancer.
Key Details of the AGM
The Annual General Meeting (AGM) is an important event for shareholders, and Sareum has scheduled it for 10:00 am on December 19, 2024. The venue for the meeting is at 88 Wood Street, London. Shareholders have the option to attend the meeting in person or watch the proceedings online through the Investor Meet Company platform.
How to Attend the AGM
Shareholders who wish to participate physically must register their intent by emailing or presenting their notice of the AGM upon arrival. For those opting for online attendance, registration on the IMC platform is mandatory. It is important to note that while online attendees will have the opportunity to watch the AGM, they will not have the capability to cast votes during the session.
Engaging with the Board
The company invites shareholders to engage with the Board by submitting questions for the Q&A session that follows the formal proceedings. Questions can be submitted through the IMC platform up until the morning before the AGM, as well as during the event itself.
Voting Guidelines for Shareholders
Sareum has streamlined the voting process for its shareholders. Voting will be accessible via the dedicated shareholder portal or by requesting a paper proxy form from Link Group. To ensure that their votes are counted, shareholders must either use the portal or submit a proxy form according to the guidelines provided.
Important Documents for Shareholders
Sareum plans to distribute the notice of the AGM along with the annual report and accounts for the fiscal year ending June 30, 2024. Shareholders who wish to receive hard copies of these documents must request them directly. Additionally, the reports will be made available on the company's official website, ensuring all shareholders have access to vital information.
Conclusion
The AGM of Sareum Holdings plc serves as an essential platform where shareholders can engage with the company, ask questions, and cast their votes on important matters. Active participation is encouraged to strengthen the relationship between shareholders and the Board.
Frequently Asked Questions
What is Sareum Holdings plc known for?
Sareum Holdings plc specializes in developing kinase inhibitors for the treatment of autoimmune diseases and cancer.
When is the AGM scheduled?
The Annual General Meeting is scheduled for 10:00 am on December 19, 2024.
How can shareholders participate in the AGM?
Shareholders can attend in person or register for online attendance via the Investor Meet Company platform.
What is the process for submitting questions during the AGM?
Shareholders can submit questions through the IMC platform until the morning of the AGM, as well as during the meeting itself.
Where can shareholders find the annual report and accounts?
The annual report and accounts will be distributed to requesting shareholders and will also be available on Sareum's official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.